Study to Evaluate the Microbiome of HIV+ Patients

Clinical Trial Title

Study evaluating the microbiome of human immunodificiency virus individuals in comparison with healthy controls.

Clinical Trial Protocol Description:

The purpose of this study is to evaluate the microbiome of human immunodeficiency virus (HIV+) individuals currently treated with ART (antiretroviral therapy) treatment. This study does not include a study intervention. There are two visits likely to last up to 4 hours total. Approximately 80 participants are expected to take part in this study at Rush University Medical Center.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Are between 18 and 65 years of age.
  • Are a healthy control or HIV+ participant on ART for at least 12 months.

You will be excluded from the study if any of the following criteria apply to you:

  • Have inflammatory bowel disease, celiac disease, or a GI cancer.
  • Are on immunosuppressive medications in last 60 days.
  • Have had an opportunistic infection in the last 60 days.
  • Have had a GI surgery.

This is a partial list of inclusion and exclusion criteria.

Study Details

Clinical Trial Investigator

Ali Keshavarzian, MD

Contact Information

Gabriella Sanzo